Rezlidhia (olutasidenib) — Highmark
relapsed or refractory acute myeloid leukemia (AML)
Initial criteria
- age ≥ 18 years
- diagnosis of relapsed or refractory AML (ICD-10 C92)
- disease is IDH1 mutation-positive as detected by an FDA-approved test
Reauthorization criteria
- prescriber attests that the member is tolerating therapy and has experienced a therapeutic response defined as either disease improvement or delayed disease progression
Approval duration
12 months